Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

September 30, 2028

Conditions
Mycobacterium Avium-intracellulare InfectionMycobacterium Infections, Nontuberculous
Interventions
BIOLOGICAL

Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine

"Subjects will be randomized to a single intradermal injection of BCG or placebo vaccine.~Participants randomized to the BCG arm will receive TICE® BCG. Freeze-dried vaccine is produced in vials, each containing 1 to 8 x\^108 colony forming units (CFU). A vial will be reconstituted in 20 mL of preservative-free saline. Administration of 0.1 mL will contain \~2x\^106 CFU, which accounts for approximately 0.25 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally."

DRUG

preservative-free saline

Patients randomized to the placebo arm will receive 0.1 mL preservative-free saline alone.

Trial Locations (1)

22908

University of Virginia Health, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER